Literature DB >> 11369842

Prevalence of cardiovascular damage in early renal disease.

A Levin1.   

Abstract

There is a large burden of cardiovascular disease in early renal disease due to multiple risk factors. Although left ventricular hypertrophy (LVH) is prevalent early in the process of progressive renal decline, it is associated with a number of modifiable risk factors (e.g. anaemia and systolic blood pressure (BP)). More importantly, treatment of modifiable risk factors in renal disease can delay progression. It is important to define anaemia physiologically and to remember that it is also associated with a number of cardiovascular risk factors that may/may not be independent of each other. In a recent prospective, multicentre Canadian study of early renal disease patients prior to dialysis (n=446), the baseline prevalence of LVH increased both with decreasing renal function and decreasing haemoglobin (Hb) levels. Notably, Hb levels within current guideline target levels were still associated with a very high degree of LVH. Over a 12-month period, only a decrease in Hb and an increase in systolic BP, and baseline left ventricular mass index (LVMI) predicted left ventricular growth. Patients whose cardiac symptoms progressed over 12 months were those who experienced a significant fall in BP and a significant increase in LVMI during that time. In the future, steps are needed to ensure early identification of both renal disease and specific risk factors. Recognizing modifiable risk factors and addressing them early in the course of renal disease will facilitate the improvement of patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369842     DOI: 10.1093/ndt/16.suppl_2.7

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  11 in total

1.  A review of risk factors for stroke in patients with chronic kidney disease.

Authors:  Fahad Saeed; Nadia Kousar; Kamran Qureshi; Thomas N Laurence
Journal:  J Vasc Interv Neurol       Date:  2009-01

2.  C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.

Authors:  Iain C Macdougall; Rowan Walker; Robert Provenzano; Fernando de Alvaro; Harold R Locay; Paul C Nader; Francesco Locatelli; Frank C Dougherty; Ulrich Beyer
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 8.237

3.  Managing anemia in patients with chronic heart failure: what do we know?

Authors:  Ankur Sandhu; Sandeep Soman; Michael Hudson; Anatole Besarab
Journal:  Vasc Health Risk Manag       Date:  2010-04-15

Review 4.  Heart failure and anemia: mechanisms and pathophysiology.

Authors:  Inder S Anand
Journal:  Heart Fail Rev       Date:  2008-01-31       Impact factor: 4.214

Review 5.  [Therapy and prophylaxis of renal failure].

Authors:  V M Brandenburg; B Heintz; J Floege
Journal:  Internist (Berl)       Date:  2003-07       Impact factor: 0.743

6.  Every-other-week darbepoetin alfa in the correction and maintenance of haemoglobin levels in elderly patients with chronic kidney disease: post hoc subanalysis of data from two clinical trials.

Authors:  Michelle W Krause; Rasib Raja; Anil Agarwal; Marcia R Silver; Debra Scarlata; Angela Sciarra; Reshma Kewalramani
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

7.  [Predictors of response to the CERA in chronic hemodialysis treatment-naive by erythropoiesis-stimulating agent].

Authors:  Mariam Ezziani; Adil Najdi; Souad Mikou; Hakim Hanin; Mohammed Arrayhani; Tarik Sqalli Houssaini
Journal:  Pan Afr Med J       Date:  2015-04-07

8.  Meta-Analysis of Randomized Controlled Trials on Androgens versus Erythropoietin for Anaemia of Chronic Kidney Disease: Implications for Developing Countries.

Authors:  B Adamu; S M Ma'aji; P J Erwin; I M Tleyjeh
Journal:  Int J Nephrol       Date:  2012-10-16

9.  Clinical management of nondialysis patients with chronic kidney disease: a retrospective observational study. Data from the SONDA study (Survey Of Non-Dialysis outpAtients).

Authors:  Massimo Morosetti; Antonio Gorini; Anna Maria Costanzo; Silvia Cipriani; Sara Dominijanni; Colin G Egan; Laura Zappalà; Umberto di Luzio Paparatti
Journal:  Int J Nephrol Renovasc Dis       Date:  2013-02-18

10.  Recombinant human epoetin beta in the treatment of renal anemia.

Authors:  Francesco Locatelli; Pietro Pozzoni; Lucia Del Vecchio
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.